Deaths / year
0
GBD (indicative unless refreshed)
DALYs / year
50,000
GBD
Pathogen
Virus
Post-infectious
Post-infectious syndrome
Persistent symptoms
~1 in 4,000–7,000 (GBS); ~5–10% maternal infections (CZS risk)
Zika infections / pregnancies
Supplemental viral disease — not on WHO NTD list.
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Documented post-infectious syndrome
Guillain-Barré syndrome; congenital Zika syndrome
~1 in 4,000–7,000 (GBS); ~5–10% maternal infections (CZS risk)
persistent symptoms — of Zika infections / pregnancies
Summary
GBS incidence elevated in outbreak settings; congenital syndrome risk highest with first-trimester maternal infection.
Timeframe
days to months post-acute
Evidence strength
moderate-strong
Classification
Post-infectious syndrome
Sources: Cao-Lormeau 2016 NEJM; WHO PAHO Zika
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Vector & transmission control
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Aedes vector control (integrated with dengue) | Vector control | Approved | Reduce Aedes aegypti/albopictus populations | WHO Zika |
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Pregnancy exposure avoidance & condom use | Prevention | Approved | Prevent congenital Zika syndrome | WHO |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Supportive care (rest, fluids, analgesia) | Supportive | Approved | No approved antiviral | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Guillain-Barré syndrome management (IVIG, plasmapheresis) | Immunotherapy | Approved | Post-infectious neuropathy | WHO; Cao-Lormeau 2016 |
| Congenital Zika syndrome multidisciplinary care | Rehabilitation | Approved | Microcephaly, developmental support | WHO PAHO |
Associated drug targets (Open Targets): AXL, CD8A, CD4, STAT2, IL1B, STAT1
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0018661 · Updated 2026-07-10. Associations, not a diagnostic test.